Trial Profile
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Age
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs GSK 2202083A (Primary) ; Hib DTaP hepatitis B poliovirus vaccine (Infanrix hexa); Meningococcal vaccine group C conjugate; Pneumococcal 10-valent vaccine conjugate; RIX 4414
- Indications Diphtheria; Haemophilus infections; Hepatitis B; Meningococcal group C infections; Pertussis; Pneumococcal infections; Poliomyelitis; Tetanus
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Sep 2009 New trial record